[{"id":"ef8c69f2-9cbe-4385-a557-591f47dd7101","acronym":"","url":"https://clinicaltrials.gov/study/NCT03381274","created_at":"2021-01-18T16:41:08.185Z","updated_at":"2024-07-02T16:34:37.847Z","phase":"Phase 1/2","brief_title":"Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study","source_id_and_acronym":"NCT03381274","lead_sponsor":"MedImmune LLC","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR T790M negative","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR T790M negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • oleclumab (MEDI9447) • imaradenant (AZD4635)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 43","initiation":"Initiation: 05/08/2018","start_date":" 05/08/2018","primary_txt":" Primary completion: 05/24/2021","primary_completion_date":" 05/24/2021","study_txt":" Completion: 07/15/2025","study_completion_date":" 07/15/2025","last_update_posted":"2024-06-06"},{"id":"839f620b-12d4-4a91-a1bc-669aefdc71c1","acronym":"","url":"https://clinicaltrials.gov/study/NCT02496663","created_at":"2024-03-06T21:31:26.529Z","updated_at":"2024-07-02T16:34:58.872Z","phase":"Phase 1","brief_title":"Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor","source_id_and_acronym":"NCT02496663","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR exon 20 mutation • EGFR T790M negative","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR exon 20 mutation • EGFR T790M negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • Portrazza (necitumumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 138","initiation":"Initiation: 05/11/2016","start_date":" 05/11/2016","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-06-04"},{"id":"659f704a-33f9-4ece-9a3f-ade7e3e42f5c","acronym":"","url":"https://clinicaltrials.gov/study/NCT06109558","created_at":"2023-10-31T18:13:38.814Z","updated_at":"2024-07-02T16:35:00.090Z","phase":"Phase 1/2","brief_title":"The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC","source_id_and_acronym":"NCT06109558","lead_sponsor":"Hunan Province Tumor Hospital","biomarkers":" EGFR • MET • RET","pipe":" | ","alterations":" MET amplification • RET fusion • EGFR T790M negative","tags":["EGFR • MET • RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification • RET fusion • EGFR T790M negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 12/31/2023","start_date":" 12/31/2023","primary_txt":" Primary completion: 12/30/2026","primary_completion_date":" 12/30/2026","study_txt":" Completion: 07/30/2027","study_completion_date":" 07/30/2027","last_update_posted":"2024-05-30"},{"id":"3aa290d8-6797-4cf2-a109-40a5ce47ce82","acronym":"NCI-2021-04325","url":"https://clinicaltrials.gov/study/NCT04940299","created_at":"2021-06-25T22:54:16.715Z","updated_at":"2024-07-02T16:35:03.655Z","phase":"Phase 2","brief_title":"Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma","source_id_and_acronym":"NCT04940299 - NCI-2021-04325","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BRAF","pipe":" | ","alterations":" EGFR mutation • BRAF mutation • BRAF V600 • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X • EGFR exon 19 deletion + EGFR L861Q • EGFR T790M negative","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • BRAF mutation • BRAF V600 • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X • EGFR exon 19 deletion + EGFR L861Q • EGFR T790M negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Actemra IV (tocilizumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 09/23/2021","start_date":" 09/23/2021","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-15"},{"id":"a44fd9da-48a5-4030-9451-0e84dbc43d2f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05430386","created_at":"2022-06-24T15:56:28.883Z","updated_at":"2024-07-02T16:35:55.559Z","phase":"Phase 1","brief_title":"Study of HS-10241 in Combination With Almonertinib in Patients With Locally Advanced or Metastatic NSCLC","source_id_and_acronym":"NCT05430386","lead_sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","biomarkers":" MET","pipe":" | ","alterations":" EGFR L858R • EGFR exon 19 deletion • MET mutation • MET positive • EGFR T790M negative • EGFR mutation + MET-CEP7 fusion • MET positive + EGFR mutation","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR L858R • EGFR exon 19 deletion • MET mutation • MET positive • EGFR T790M negative • EGFR mutation + MET-CEP7 fusion • MET positive + EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ameile (aumolertinib) • dalmelitinib (HS-10241)"],"overall_status":"Recruiting","enrollment":" Enrollment 174","initiation":"Initiation: 01/05/2022","start_date":" 01/05/2022","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2023-02-14"},{"id":"48b8d938-7f8b-4bf9-a8a6-3d05476c8d31","acronym":"","url":"https://clinicaltrials.gov/study/NCT03758287","created_at":"2021-01-17T17:24:54.380Z","updated_at":"2024-07-02T16:36:08.487Z","phase":"Phase 1/2","brief_title":"Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative","source_id_and_acronym":"NCT03758287","lead_sponsor":"Sunshine Lake Pharma Co., Ltd.","biomarkers":" MET","pipe":" | ","alterations":" EGFR mutation • EGFR T790M negative","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR T790M negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gefitinib • ningetinib (CT053PTSA)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 158","initiation":"Initiation: 11/01/2016","start_date":" 11/01/2016","primary_txt":" Primary completion: 07/17/2023","primary_completion_date":" 07/17/2023","study_txt":" Completion: 07/17/2023","study_completion_date":" 07/17/2023","last_update_posted":"2022-06-22"},{"id":"40ca0fe6-acc3-4662-bc45-3488f9464ecc","acronym":"","url":"https://clinicaltrials.gov/study/NCT04116918","created_at":"2021-01-18T20:07:23.223Z","updated_at":"2024-07-02T16:36:54.843Z","phase":"","brief_title":"Efficacy and Safety of the Combination of Anlotinib and JS001 in EGFR-TKI Resistant T790M-Negative NSCLC","source_id_and_acronym":"NCT04116918","lead_sponsor":"Baodong Qin","biomarkers":" BRAF","pipe":" | ","alterations":" EGFR mutation • EGFR T790M negative","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR T790M negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Focus V (anlotinib) • Loqtorzi (toripalimab-tpzi)"],"overall_status":"Unknown status","enrollment":" Enrollment 100","initiation":"Initiation: 09/01/2019","start_date":" 09/01/2019","primary_txt":" Primary completion: 09/30/2021","primary_completion_date":" 09/30/2021","study_txt":" Completion: 09/30/2021","study_completion_date":" 09/30/2021","last_update_posted":"2019-10-07"}]